Any current/future new fundraising through debt or equity?

Solara Active Pharma Sciences is planning a rights issue to raise funds, with board approval for up to INR 450 crores. The expected amount to be raised is approximately INR 350 to 400 crores, pending finalization based on the reset plan and cash needs. The rights issue proceeds will primarily be used for debt reduction; no new capital expenditure is planned. Promoters intend to subscribe to their rights and are willing to underwrite any unsubscribed portion, reflecting confidence in the company's turnaround. There is no mention of additional debt fundraising beyond this rights issue fo

Any current/future capex/capital investment/strategic investment?

No major new capex planned for the near future as significant new capacities are currently underutilized. Recurring capex requirement is estimated between INR 40 crores to INR 50 crores per year. Focus will be on network optimization and capacity utilization rather than new capital investments. Rights issue proceeds (expected INR 350-400 crores) are primarily aimed at debt reduction, not capex. Strategic focus includes cost improvements, portfolio maximization, and customer acquisitions rather than capital expenditure. R&D spend will be sharpened to enhance outcomes and revive dormant DMFs rat

Future growth expectations in sales/revenue/volumes?

FY '25 revenue guidance is around INR 1,500 crores, roughly flattish compared to FY '24 adjusted for the fire incident. Focus for the next 4 quarters is primarily on margin expansion rather than aggressive top-line growth. Growth is expected to resume in H2 FY '25 with new customer acquisitions and new products being seeded. Historical growth in the last 2 years impacted margins due to network over-utilization; future growth will be more margin-focused. The company aims for a calibrated, quarter-on-quarter improvement in revenue quality starting Q1 FY '25. Emphasis on cost improvements, portfo

Future growth expectations in earnings/operating earnings/profits/EPS?

Solara expects a reset strategy to double EBITDA by Q4 FY 2025, targeting 20-22% EBITDA margin (Page 6). Guidance for FY 2025 includes INR 1,500 crores top-line with focus on margin expansion over volume growth initially (Page 7). Margin expansion of around 500-600 basis points anticipated through cost savings and product mix improvement (Page 7). EBITDA margin expected to rise from mid-40% to historic 51-52% gross margins gradually over 5 quarters (Page 7). Free cash generation projected at around INR 150 crores next year, supporting debt reduction and operational efficiency (Page 8). Managem

Current/ Expected Orderbook/ Pending Orders?

The company has a strong order book heading into FY '25 as referenced in the reset strategy. Production disruptions due to the fire incident in Q3 delayed shipments, but sales shifted to Q4. Guidance for FY '25 is based on a stronger order book, expected to improve quarterly performance. They are confident in quality growth and margin expansion driven by this order book. No explicit numeric value of the current or expected order book was disclosed in the transcript.

IN US

Sale is live|00:00:00left today

Solara Active Pharma Sciences LtdQ4 FY25Pharmaceuticals & Biotechnology

Solara Active Pharma Sciences Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹570Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

→FY '25 revenue guidance is around INR 1,500 crores, roughly flattish compared to FY '24 adjusted for the fire incident.
→Focus for the next 4 quarters is primarily on margin expansion rather than aggressive top-line growth.
→Growth is expected to resume in H2 FY '25 with new customer acquisitions and new products being seeded.
→Historical growth in the last 2 years impacted margins due to network over-utilization; future growth will be more margin-focused.
→The company aims for a calibrated, quarter-on-quarter improvement in revenue quality starting Q1 FY '25.
→Emphasis on cost improvements, portfolio maximization, and network optimization to enable sustainable volume growth alongside margin expansion.

Margin guidance

Category 1

→Solara expects a reset strategy to double EBITDA by Q4 FY 2025, targeting 20-22% EBITDA margin (Page 6).
→Guidance for FY 2025 includes INR 1,500 crores top-line with focus on margin expansion over volume growth initially (Page 7).
→Margin expansion of around 500-600 basis points anticipated through cost savings and product mix improvement (Page 7).
→EBITDA margin expected to rise from mid-40% to historic 51-52% gross margins gradually over 5 quarters (Page 7).
→Free cash generation projected at around INR 150 crores next year, supporting debt reduction and operational efficiency (Page 8).
→Management aims for a sustainable return to historical EBITDA levels (~INR 40 crores per quarter) and cautious growth thereafter (Page 6-7).
→Growth expected to pick up in H2 FY 2025 after initial focus on margin and operational reset (Page 7).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Solara Active Pharma Sciences is planning a rights issue to raise funds, with board approval for up to INR 450 crores.
→The expected amount to be raised is approximately INR 350 to 400 crores, pending finalization based on the reset plan and cash needs.
→The rights issue proceeds will primarily be used for debt reduction; no new capital expenditure is planned.
→Promoters intend to subscribe to their rights and are willing to underwrite any unsubscribed portion, reflecting confidence in the company's turnaround.
→There is no mention of additional debt fundraising beyond this rights issue for now.
→The company aims to improve its debt-to-EBITDA ratio to under 3, targeting around 2.5, supported by free cash flow and rights issue proceeds.

Order book

→The company has a strong order book heading into FY '25 as referenced in the reset strategy.
→Production disruptions due to the fire incident in Q3 delayed shipments, but sales shifted to Q4.
→Guidance for FY '25 is based on a stronger order book, expected to improve quarterly performance.
→They are confident in quality growth and margin expansion driven by this order book.
→No explicit numeric value of the current or expected order book was disclosed in the transcript.

Capex plans

→No major new capex planned for the near future as significant new capacities are currently underutilized.
→Recurring capex requirement is estimated between INR 40 crores to INR 50 crores per year.
→Focus will be on network optimization and capacity utilization rather than new capital investments.
→Rights issue proceeds (expected INR 350-400 crores) are primarily aimed at debt reduction, not capex.
→Strategic focus includes cost improvements, portfolio maximization, and customer acquisitions rather than capital expenditure.
→R&D spend will be sharpened to enhance outcomes and revive dormant DMFs rather than broad, high spending.
→Overall approach is to manage existing assets efficiently and improve margins with limited capital expenditure going forward.

How does Solara Active Pharma Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Solara Active Pharma Sciences Ltd

Rev 4Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Solara Active Pharma Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio